Effectiveness of icotinib against non–small-cell lung cancer with uncommon EGFR mutations.

作者：Shengyu Zhou, Xingsheng Hu, Yan Wang, Junling Li, Liqiang Zhou, Xuezhi Hao, Yutao Liu, Yuankai Shi · 发表于：Journal of Clinical Oncology · 年份：2018 · DOI：10.1200/jco.2018.36.15_suppl.e21083 · 被引用次数：3 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies

e21083 Background: Epidermal growth factor receptor (EGFR) gene mutations other than 19 Del and 21 L858R have not been fully described due to their rarity. Here we present a retrospective study to evaluate the efficacy of icotinib, an EGFR TKI in non-small-cell lung cancer patients with uncommon EGFR mutations. Methods: We retrospectively reviewed the clinical-pathological and effectiveness data for 100 consecutive patients with advanced NSCLC who were responsive to icotinib treatment. Patients with 19 Del alone, or EGFR 21 L858R alone were chosen as comparison. Results: Among 100 patients, 85 and 15 had common and uncommon mutations, respectively. Four patients had a single mutation in 18 or 20 exon, and 11 had a complex mutation with del-19 or L858R. There was no significant association between the presence of different mutation type and the type of any clinical and pathological characteristics. Prolonged but not significant progression-free survival (PFS) was noted in patients with common EGFR mutations [18.07 (14-26.23) vs 12.9 (8.43-23.27), p = 0.056]. Patients without brain metastases had increased PFS to icotinib than those with brain metastases (18.07 [95%CI14.77-27.03] vs 13.17 [8.63-22.63], p = 0.038). Conclusions: Our findings suggested that patients with uncommon mutations, especially complex mutations, had favorable clinical benefits from icotinib. However, the heterogeneous sensitivity to EGFR TKI of uncommon EGFR mutations should be considered when making clini...